Perioperative management and outcomes of hip and knee arthroplasty among heartmate 3 left ventricular assist device recipients
Research article published in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie (2026)
Abstract
PURPOSE: We aimed to evaluate preoperative cardiovascular assessment, perioperative management, and outcomes in HM3 recipients undergoing hip or knee arthroplasty. METHODS: This retrospective case series included six patients with HM3 LVADs undergoing total hip or knee arthroplasty. Mean age was 67.4 ± 5.7 years; two were female, and two had ischemic cardiomyopathy. Average ejection fraction was 15 ± 4.5%. RESULTS: Procedures included three knee arthroplasties (50%), two total hip arthroplasties (33.3%), and one hip hemiarthroplasty (16.7%). Median time from LVAD implantation to arthroplasty was 19.2 ± 13.6 months. Patients were admitted an average of 2.7 ± 1.8 days preoperatively; mean postoperative length of stay was 13 days. All patients were anticoagulated with warfarin (mean INR 1.4 ± 0.2), with five requiring heparin bridging. LVAD-related infections developed in three patients (50%), and two (33%) required readmission. At final follow-up, two patients (33%) had died, at a mean of 28 ± 8 months post-arthroplasty and 47 ± 36 months after HM3 implantation. CONCLUSION: Hip and knee arthroplasty in HM3 LVAD recipients can be performed with perioperative management strategies that mitigate excess mortality beyond expected LVAD outcomes. These findings highlight the importance of specialized perioperative care in improving the safety and feasibility of arthroplasty in HM3 LVAD patients. Larger studies with longer follow-up are needed to refine patient selection, optimize perioperative care, and clarify the value of arthroplasty in this complex population.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Esta serie de casos retrospectiva de seis receptores de LVAD HeartMate 3 sometidos a artroplastia de cadera o rodilla describió su manejo de anticoagulación perioperatoria, todos con warfarin (INR medio de 1,4) y cinco de los cuales requirieron un puente con heparin, e informó tasas de complicaciones notables, incluyendo infección relacionada con el LVAD en tres pacientes y dos muertes en el seguimiento final. Su vínculo con la hirudoterapia es indirecto, situándose en la literatura sobre anticoagulación perioperatoria y el manejo de sangrado frente a trombosis, en lugar de involucrar sanguijuelas; las sanguijuelas medicinales no forman parte de este estudio. La advertencia honesta es que se trata de una serie de casos muy pequeña, de un único centro, de seis pacientes con el dispositivo y sin intervención con sanguijuelas, por lo que cualquier relación con la hirudoterapia es únicamente de contexto general, no evidencia a favor o en contra del uso de sanguijuelas.
Citación
Perioperative management and outcomes of hip and knee arthroplasty among heartmate 3 left ventricular assist device recipients.
Turan et al. · European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2026
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026